The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index; none of the 57 sources its claims cite is checked for support yet.
Clearance kinetics of the VGF-derived neuropeptide TLQP-21
Open accessAbstract
TLQP-21 is a multifunctional neuropeptide and a promising new medicinal target for cardiometabolic and neurological diseases. However, to date its clearance kinetics and plasma stability have not been studied. The presence of four arginine residues led us to hypothesize that its half-life is relatively short. Conversely, its biological activities led us to hypothesize that the peptide is still taken up by adipose tissues effectively. [125 I]TLQP-21 was i.v. administered in rats followed by chasing the plasma radioactivity and assessing tissue uptake. Plasma stability was measured using LC-MS. In vivo lipolysis was assessed by the palmitate rate of appearance. Results A small single i.v. dose of [125 I]TLQP-21 had a terminal half-life of 110 min with a terminal clearance rate constant, k t, of 0.0063/min, and an initial half-life of 0.97 min with an initial clearance rate constant, k i, of 0.71/min. The total net uptake by adipose tissue accounts for 4.4% of the entire dose equivalent while the liver, pancreas and adrenal gland showed higher uptake. Uptake by the brain was negligible, suggesting that i.v.-injected peptide does not cross the blood-brain-barrier. TLQP-21 sustained isoproterenol-stimulated lipolysis in vivo. Finally, TLQP-21 was rapidly degraded producing several N-terminal and central sequence fragments after 10 and 60 min in plasma in vitro. This study investigated the clearance and stability of TLQP-21 peptide for the first time. While its pro-lipolytic effect supports and extends previous findings, its short half-life and sequential cleavage in the plasma suggest strategies for chemical modifications in order to enhance its stability and therapeutic efficacy.
Overview
CoChat Summary
TL;DR
This study provides the first characterization of TLQP-21 clearance kinetics and plasma stability, showing a short initial half-life and rapid plasma degradation despite sustained pro-lipolytic activity in rats. The authors conclude that chemical modification may be needed to improve TLQP-21 stability and therapeutic efficacy.
Key findings
- After i.v. bolus of [125I]TLQP-21 in rats, plasma clearance was exponential: corrected initial half-life was 0.97 min (ki′ = 0.71/min) and terminal half-life was 110 min (kt = 0.0063/min). The paper reports mean residence time 159 min, terminal volume of distribution 4258 ml/kg, total body clearance 27.1 ml/kg/min, and that 99% of injected peptide would be cleared in 6.4 min at the initial rate.
- Total net uptake by adipose tissue accounted for 4.4% of the entire dose equivalent; liver, pancreas, and adrenal gland showed higher uptake, while brain uptake was negligible, suggesting i.v.-injected peptide does not cross the blood-brain barrier. Pancreas and kidney had the greatest uptake per tissue weight/protein; adipose tissue had the least per unit weight but was comparable per tissue protein; skeletal muscle was a major whole-organ site due to its mass. C3aR1 expression was highest in liver, adipose tissue, and heart, lower in brain, and negligible in skeletal muscle.
- In 100% mouse plasma, full-length TLQP-21 was not identifiable after 10 min. At 10 min the most enriched fragment was TLQPPASSRRRHFHHALPPA, suggesting the C-terminal arginine is cleaved first; HFHHALPPAR indicated central arginines are also rapidly cleaved. At 60 min, only N-terminal hexa- and hepta-peptides and HFHHALPPA remained.
- TLQP-21 sustained isoproterenol-stimulated lipolysis in vivo: palmitate rate of appearance was 29% greater in the TLQP-21-treated group than in vehicle-treated controls, and plasma palmitate AUCs differed significantly between groups. Control plasma palmitate fell to ~75% of initial value, whereas it was sustained in the TLQP-21 group.
Methods
- Two series of experiments used male Sprague Dawley rats on regular rodent chow (4.5% dietary fat), conducted in the morning without prior fasting. For clearance/tissue distribution, rats (n=8, ~400 g) received i.v. [125I]TLQP-21 (6–10 μCi, specific activity ~0.25 μCi/μg), with repeated blood collections at 5-min intervals for 20 min, followed by tissue collection.
- For lipolysis, rats (n=8) received constant i.v. [U-13C]palmitate at 0.5 μmol·kg−1·min−1, then isoproterenol at 30 ng·min−1, followed by a bolus of 40 μg TLQP-21 or saline; blood was sampled for 60 min, and plasma palmitate concentration AUC and palmitate Ra were measured.
- Plasma stability used TLQP-21 incubated in 100% mouse plasma at 1 mM at 37°C for 0, 10, 30, and 60 min, with LC-MS analysis. C3aR1 expression was measured by QPCR in selected organs. Statistics used mean±SEM, non-paired Student’s t-test, single-factor ANOVA with Tukey post hoc, and α=0.05.
Limitations
- The paper states that tissue uptake is net uptake only; reversal/release was not measured, so gross uptake is assumed to be greater. It also states that significance of uptake by pancreas, kidney, and adrenals is premature to speculate, that the precise function of TLQP-21 in myocytes remains to be clarified, that the heart was not tested for ligand-receptor binding, and that whether the peptide alters FFA uptake remains to be determined.
- The paper states that the hypothesis that larger or more frequent doses could prolong half-life needs validation in future investigations.
- Evident from the text: experiments used only male Sprague Dawley rats (n=8 per protocol), without fasting, and plasma stability was tested in 100% mouse plasma in vitro at 1 mM rather than in rat or human plasma or at the low in vivo dose (<0.1 mg/kg), limiting direct translation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 0 Not valid · 31 Not checked · 69 Own results and interpretations
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At this clearance rate, 99% of the injected peptide is cleared in 6.4 min (i.e. in 6.6 half-lives)”
§ Clearance kinetics of the VGF-derived Neuropeptide TLQP-21 > RESULTS > TLQP-21 clearance kinetics
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Its in vivo half-life is found to be relatively short following a small, acute bolus injection.”
§ Clearance kinetics of the VGF-derived Neuropeptide TLQP-21 > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, several fragments, which represent the product of proteolytic cleavage by prohormone convertase, could be identified (Table 2 and Figure 3).”
§ Clearance kinetics of the VGF-derived Neuropeptide TLQP-21 > RESULTS > Stability of TLQP-21 in mouse plasma
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In line with the in vivo clearance study, the full length peptide was not identifiable after 10 minutes.”
§ Clearance kinetics of the VGF-derived Neuropeptide TLQP-21 > RESULTS > Stability of TLQP-21 in mouse plasma
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Excluding the brain, all other organs assessed have a similar peptide uptake when this is normalized by tissue protein content (Table 1).”
§ Clearance kinetics of the VGF-derived Neuropeptide TLQP-21 > RESULTS > Tissue uptake and distribution of TLQP-21
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
48 more claims
Create a free account to see all 100 claims and to verify the 49 references still open.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 19
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clearance kinetics of the VGF-derived Neuropeptide TLQP-21 > DISCUSSION
“By mutating the Arg21 into Arg21”
§ Clearance kinetics of the VGF-derived Neuropeptide TLQP-21 > DISCUSSION
“R21A peptide”
Citations
Cites
A RELATION BETWEEN NON-ESTERIFIED FATTY ACIDS IN PLASMA AND THE METABOLISM OF GLUCOSE
Dole, V. P. (1956) · Journal of Clinical Investigation · doi:10.1172/jci103259 · Cited by 3,454
Physiological Parameters in Laboratory Animals and Humans
Davies, B., & Morris, T. (1993) · Pharmaceutical Research · doi:10.1023/a:1018943613122 · Cited by 2,926
Critical review of acylation-stimulating protein physiology in humans and rodents
Cianflone, K., Xia, Z., & Chen, L. Y. (2003) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(02)00686-7 · Cited by 364
The Extended Granin Family: Structure, Function, and Biomedical Implications
Bartolomucci, A., Possenti, R., Mahata, S. K., Fischer-Colbrie, R., Loh, Y. P., & Salton, S. R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0027 · Cited by 348
Self-citationChange Trends of Organ Weight Background Data in Sprague Dawley Rats at Different Ages
Piao, Y., Liu, Y., & Xie, X. (2013) · Journal of Toxicologic Pathology · doi:10.1293/tox.26.29 · Cited by 243
The Relation of Metabolic Rate to Body Weight and Organ Size
Holliday, M. A., Potter, D., Jarrah, A., & Bearg, S. (1967) · Pediatric Research · doi:10.1203/00006450-196705000-00005 · Cited by 175
Regulation of Dietary Fatty Acid Entrapment in Subcutaneous Adipose Tissue and Skeletal Muscle
Evans, K., Burdge, G. C., Wootton, S. A., Clark, M. L., & Frayn, K. N. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2684 · Cited by 161
Bartolomucci, A., La Corte, G., Possenti, R., Locatelli, V., Rigamonti, A. E., Torsello, A., Bresciani, E., Bulgarelli, I., Rizzi, R., Pavone, F., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606102103 · Cited by 134
Self-citationMurray, I., Havel, P. J., Sniderman, A. D., & Cianflone, K. (2000) · Endocrinology · doi:10.1210/endo.141.3.7364 · Cited by 109
Hannedouche, S., Beck, V., Leighton-Davies, J. R., Beibel, M., Roma, G., Oakeley, E. J., Lannoy, V. J., Bernard, J., Hamon, J., Barbieri, S., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.497214 · Cited by 96
Stephens, S. B., Schisler, J. C., Hohmeier, H. E., An, J., Sun, A. Y., Pitt, G. S., & Newgard, C. B. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.05.011 · Cited by 89
VGF-derived peptide, TLQP-21, regulates food intake and body weight in Siberian hamsters
Jethwa, P. H., Warner, A., Nilaweera, K. N., Brameld, J. M., Keyte, J. W., Carter, W. G., Bolton, N., Bruggraber, M., Morgan, P. J., Barrett, P., et al. (2007) · Endocrinology · doi:10.1210/en.2007-0038 · Cited by 77
Tissue-specific processing of the neuroendocrine protein VGF
Trani, E., Ciotti, T., Rinaldi, A. M., Canu, N., Ferri, G. L., Levi, A., & Possenti, R. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65062441.x · Cited by 64
Cero, C., Vostrikov, V. V., Verardi, R., Severini, C., Gopinath, T., Braun, P. D., Sassano, M. F., Gurney, A., Roth, B. L., Vulchanova, L., et al. (2014) · Structure · doi:10.1016/j.str.2014.10.001 · Cited by 62
Self-citationThe prohormone VGF regulates β cell function via insulin secretory granule biogenesis
Stephens, S. B., Edwards, R. J., Sadahiro, M., Lin, W.-J., Jiang, C., Salton, S. R., & Newgard, C. B. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.050 · Cited by 62
Possenti, R., Muccioli, G., Petrocchi, P., Cero, C., Cabassi, A., Vulchanova, L., Riedl, M. S., Manieri, M., Frontini, A., Giordano, A., et al. (2012) · Biochemical Journal · doi:10.1042/bj20111165 · Cited by 58
Self-citationFairbanks, C. A., Peterson, C. D., Speltz, R., Riedl, M. S., Kitto, K. F., Dykstra, J. A., Braun, P. D., Sadahiro, M., Salton, S. R., & Vulchanova, L. (2014) · Pain · doi:10.1016/j.pain.2014.03.012 · Cited by 57
The VGF-derived peptide TLQP-21: A new modulatory peptide for inflammatory pain
Rizzi, R., Bartolomucci, A., Moles, A., D'Amato, F. R., Sacerdote, P., Levi, A., Corte, G. L., Ciotti, M. T., Possenti, R., & Pavone, F. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.06.018 · Cited by 49
Self-citationFree fatty acid turnover measured using ultralow doses of [U-13C]palmitate
Guo, Z., Nielsen, S., Burguera, B. G., & Jensen, M. D. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37163-7 · Cited by 49
Self-citationFargali, S., Garcia, A. L., Sadahiro, M., Jiang, C., Janssen, W. G., Lin, W., Cogliani, V., Elste, A., Mortillo, S., Cero, C., et al. (2014) · The FASEB Journal · doi:10.1096/fj.13-239509 · Cited by 46
Self-citationCero, C., Razzoli, M., Han, R., Sahu, B. S., Patricelli, J., Guo, Z., Zaidman, N. A., Miles, J. M., O'Grady, S. M., & Bartolomucci, A. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2016.10.005 · Cited by 43
Self-citationTriglyceride Content in Skeletal Muscle: Variability and the Source
Guo, Z. (2001) · Analytical Biochemistry · doi:10.1006/abio.2001.5233 · Cited by 41
Self-citationWagner, L., Kaestner, F., Wolf, R., Stiller, H., Heiser, U. F., Manhart, S., Hoffmann, T., Rahfeld, J., Demuth, H., Rothermundt, M., et al. (2016) · Neuropeptides · doi:10.1016/j.npep.2016.02.007 · Cited by 40
Severini, C., La Corte, G., Improta, G., Broccardo, M., Agostini, S., Petrella, C., Sibilia, V, Pagani, F., Guidobono, F., Bulgarelli, I., et al. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00192.x · Cited by 38
Complement 3a receptor in dorsal horn microglia mediates pronociceptive neuropeptide signaling
Doolen, S., Cook, J., Riedl, M., Kitto, K., Kohsaka, S., Honda, C. N., Fairbanks, C. A., Taylor, B. K., & Vulchanova, L. (2017) · Glia · doi:10.1002/glia.23208 · Cited by 38
Effect of Age and Sex on Rat Endocrine Pancreas
REAVEN, E. P., CURRY, D. L., & Reaven, G. M. (1987) · Diabetes · doi:10.2337/diab.36.12.1397 · Cited by 31
Implication of the VGF-derived peptide TLQP-21 in mouse acute and chronic stress responses
Razzoli, M., Bo, E., Pascucci, T., Pavone, F., D'Amato, F. R., Cero, C., Sanghez, V., Dadomo, H., Palanza, P., Parmigiani, S., et al. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.01.038 · Cited by 25
Self-citationThe VGF-derived peptide TLQP-62 modulates insulin secretion and glucose homeostasis
Petrocchi-Passeri, P., Cero, C., Cutarelli, A., Frank, C., Severini, C., Bartolomucci, A., & Possenti, R. (2015) · Journal of Molecular Endocrinology · doi:10.1530/jme-14-0313 · Cited by 23
Self-citationGuo, Z., & Zhou, L. (2003) · Lab Animal · doi:10.1038/laban0203-45 · Cited by 23
Self-citationAguilar, E., Pineda, R., Gaytán, F., Sanchez-Garrido, M. A., Romero, M., Romero‐Ruíz, A., Ruíz-Pino, F., Tena‐Sempere, M., & Pinilla, L. (2013) · Neuroendocrinology · doi:10.1159/000350323 · Cited by 23
GERBER, N., WELLER, W. L., LYNN, R., RANGNO, R. E., SWEETMAN, B. J., & BUSH, M. T. (1971) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)28989-3 · Cited by 23
Kostelnik, K. B., Els-Heindl, S., Klöting, N., Baumann, S., von Bergen, M., & Beck-Sickinger, A. G. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.12.008 · Cited by 21
Lipolytic responsiveness to epinephrine in nondiabetic and diabetic humans
Divertie, G. D., Jensen, M. D., Cryer, P. E., & Miles, J. M. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.272.6.e1130 · Cited by 21
Self-citationCassina, V., Torsello, A., Tempestini, A., Salerno, D., Brogioli, D., Tamiazzo, L., Bresciani, E., Martinez, J., Fehrentz, J. A., Verdié, P., et al. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2012.10.023 · Cited by 18
Molteni, L., Rizzi, L., Bresciani, E., Possenti, R., Passeri, P. P., Ghé, C., Muccioli, G., Fehrentz, J., Verdié, P., Martínez, J., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00167 · Cited by 18
Berezhkovskiy, L. M. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23396 · Cited by 16
Nelson, R. H., Edgerton, D. S., Basu, R., Roesner, J. C., Cherrington, A. D., & Miles, J. M. (2007) · Diabetes · doi:10.2337/db06-1657 · Cited by 15
Self-citationTLQP-21, a VGF-derived peptide, stimulates exocrine pancreatic secretion in the rat
Petrella, C., Broccardo, M., Possenti, R., Severini, C., & Improta, G. (2012) · Peptides · doi:10.1016/j.peptides.2012.03.035 · Cited by 11
Adam, A. A., Leclair, P., Montpas, N., Koumbadinga, G. A., Bachelard, H., & Marceau, F. (2009) · Neuropeptides · doi:10.1016/j.npep.2009.09.004 · Cited by 11
Gros, C., Souque, A., & Schwartz, J.-C. (1990) · Neuropeptides · doi:10.1016/0143-4179(90)90133-j · Cited by 11
Choi, Y. H., Lee, I., & Lee, M. G. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.05.006 · Cited by 9
Embryonic ablation of neuronal VGF increases energy expenditure and reduces body weight
Jiang, C., Lin, W.-J., Sadahiro, M., Shin, A. C., Buettner, C., & Salton, S. R. (2017) · Neuropeptides · doi:10.1016/j.npep.2016.12.005 · Cited by 8
On the Accuracy of a One-Compartment Approach for Determination of Drug Terminal Half-Life
Berezhkovskiy, L. M. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23565 · Cited by 6
Cited by
Kim, J., Bai, Y., Jayne, L. A., Abdulkader, F., Gandhi, M., Perreau, T., Parikh, S. V., Gardner, D. S., Davidson, A. J., Sander, V., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.015110 · Cited by 32
Functional profiling of the G protein-coupled receptor C3aR1 reveals ligand-mediated biased agonism
Rodriguez, P., Laskowski, L. J., Pallais, J. P., Bock, H. A., Cavalco, N. G., Anderson, E. I., Calkins, M. M., Razzoli, M., Sham, Y. Y., McCorvy, J. D., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105549 · Cited by 30
Self-citationComplement C3aR signaling: Immune and metabolic modulation and its impact on Alzheimer's disease
Gedam, M., & Zheng, H. (2024) · European Journal of Immunology · doi:10.1002/eji.202350815 · Cited by 27
Peptide/Receptor Co-evolution Explains the Lipolytic Function of the Neuropeptide TLQP-21
Sahu, B. S., Rodriguez, P., Nguyen, M. E., Han, R., Cero, C., Razzoli, M., Piaggi, P., Laskowski, L. J., Pavlicev, M., Muglia, L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.101 · Cited by 26
Self-citationBresciani, E., Possenti, R., Coco, S., Rizzi, L., Meanti, R., Molteni, L., Locatelli, V., & Torsello, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010130 · Cited by 22
Metadata
- Authors
- Guo, Z., Sahu, B. S., He, R., Finan, B., Cero, C., Verardi, R., Razzoli, M., Veglia, G., Di Marchi, R. D., Miles, J. M., & Bartolomucci, A.
- Affiliations
- Mayo Clinic (US)
- University of Minnesota (US)
- Corresponding author
- Bartolomucci, Alessandro
- ORCID
- Venue
- Neuropeptides
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 71
- Pages
- 97-103
- ISSN
- 0143-4179 (ISSN-L)
- PMC
- PMC6166661
- OpenAlex
- W2809384620
- Cited by
- 21
- References
- 45
- Citations by year
- 2025: 3 · 2024: 1 · 2023: 3 · 2021: 3 · 2020: 6 · 2019: 4 · 2018: 1
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (am, 356 d)
- Locations
- Neuropeptides (acceptedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH, and Decade of Discovery in Diabetes Grant, Minnesota Partnership for Biotechnology and Medical Genomic (R01DK102496, RO1 HL67933)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Health Sciences › Medicine › Pharmacology (medical) › Apelin-related biomedical research
- Keywords
- TLQP-21, plasma stability, peptide degradation, lipolysis, isoproterenol, blood-brain barrier, arginine-rich peptides, peptide modification, cardiometabolic disease, neurological disorders
- MeSH terms
- Animals, Lipolysis, Male, Metabolic Clearance Rate, Peptide Fragments, Rats, Sprague-Dawley, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-18, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-18 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.